Pharmacoeconomic analysis of different treatment regimens for Crimean hemorrhagic fever

In recent years, the efficiency of therapy for various diseases has been evaluated not опіу by clinical and laboratory parameters, but also by pharmacoeconomic indicators. Objective. To carry out a pharmacoeconomic analysis of the efficiency of Crimean hemorrhagic fever (CHF) therapy with ribavirin and immunized convalescent plasma, performed in the Republic of Kazakhstan Subjects and methods. The investigation enrolled 94 CHF patients treated at hospitals in the endemic areas of southern Kazakhstan in 2001-2019. Group 1 patients (n = 32) received only pathogenetic therapy according to the clinical diagnostic and treatment protocol used in the Republic of Kazakhstan. Group 2 patients (n = 32) were additionally treated with ribavirin according to the WHO regimen. Group 3 patients (n = 30) had combination therapy with ribavirin and immunized plasma from CHF convalescents. The overall cost of illness (COI) and cost-effectiveness analysis (CEA) were determined to provide a comparative pharmacoeconomic evaluation of the treatment regimens. Results. The mortality rates were 15.6, 9.4, and 3.3% in Groups 1, 2, and 3, respectively. A higher average amount of money spent on medications per patient in Group 3 than that in Groups 1 and 2 did not lead to a statistically significant difference in overall COI. CEA studies showed that the lowest costs per unit of treatment efficiency were in Group 3: these were 2.5 and 1.5 times lower in Group 3 than in Groups 1 and 2, respectively. CEA was 1.6 times less in Group 2 than in Group 1. Conclusion. The use of ribavirin and immunized plasma to treat CHF contributed to a more rapid reduction in the clinical and laboratory manifestations of the disease, reduced the risk of death. This treatment regimen is most beneficial in the pharmacoeconomic indicator CEA.

Crimean hemorrhagic fever, pharmacoeconomic analysis, ribavirin, immunized plasma